跳至主要内容
临床试验/ACTRN12610000378022
ACTRN12610000378022已完成2 期

The effect of oral metformin on spirometry, exercise capacity and quality of life in adults with chronic obstructive pulmonary disease (COPD) and either diet-controlled type 2 diabetes mellitus or impaired glucose tolerance.

Dr Paul Sexton0 个研究点目标入组 40 人开始时间: 2010年5月11日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
45 Years 至 o limit(—)
性别
All

入选标准

  • *Obese (body mass index > 30)
  • *Central pattern of obesity (elevated waist circumference)
  • *Impaired glucose tolerance or diet-controlled type 2 diabetes mellitus (previous diagnosis, or evidence of blood tests meeting American Diabetes Association 2010 criteria)
  • *Post-bronchodilator spirometry that is consistent with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2+ COPD
  • *Symptomatic: Medical Research Council dyspnoea score of 2 or higher

排除标准

  • 1.Currently taking oral hypoglycaemic agent or insulin
  • 2.Active respiratory disease other than obstructive airways disease
  • 3.Exacerbation of airways disease requiring change in treatment within the preceding 6 weeks
  • 4.Participation in pulmonary rehabilitation programme within the past 6 weeks
  • 5.Currently prescribed long term oral corticosteroids
  • 6.Renal impairment (estimated glomerular filtration rate < 45 mL/min)
  • 7.Cirrhosis, impaired synthetic liver function, or liver failure
  • 8.Chronic respiratory failure
  • 9.Congestive heart failure
  • 10.Current or recent habitual heavy alcohol intake
  • 11.Current use of antiretroviral medication
  • 12.Pregnancy
  • 13.History of lactic acidosis
  • 14.Allergy to metformin
  • 15.Unable to comply with the study procedures or protocol

研究者

发起方
Dr Paul Sexton

相似试验